Beone Medicines Ltd 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Beone Medicines Ltd 's ROA in the third quarter of 2026?
Beone Medicines Ltd achieved a return on average assets (ROA) of 10.1 % in its third quarter of 2026, this is above ONC's average return on assets of -23.37%.
Beone Medicines Ltd s assets during the 12 months ending in the third quarter of 2026 are valued at $9 billion

ROA has improved compared to 7.79% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 93 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 936, from total ROA ranking in the second quarter of 2026 at 1581.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	34.63 %	51.02 %	50.09 %	42.97 %	31.04 %
Y / Y Net Income Change	208.16 %	151.28 %	17802.13 %	-	-
Net Income (TTM) in million	916	656	513	287	69
Return On Assets (TTM)	10.1 %	7.79 %	6.73 %	4.15 %	1.09 %
ONC's Total Ranking	# 936	# 1581	# 2171	# 2906	# 3201
Total Assets (TTM) in million	10,116	9,317	8,554	8,267	7,514
Seq. Total Assets Change	8.58 %	8.92 %	3.47 %	10.02 %	21.8 %
Seq. Net Income Change	62.32 %	4.24 %	241.88 %	-46.73 %	32.36 %

ONC's 5 Years Annual ROA >> Back to ONC Management Effectiveness >> Compare ONC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 37
Sector	# 94
Overall	# 586

Return On Assets Statistics
High	Average	Low
10.23 %	-23.37 %	-61.32 %
(Sep 30 2026)		(Jun 30 2017)

Financial Statements
Beone Medicines Ltd 's Assets	$ 10,116 million	ONC's Balance sheet
Beone Medicines Ltd 's Income	$ 385 million	Quarterly ONC's Income Statement
ONC's Income by Division		See ONC's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	41.62 %	1.25 %	-8.95 %	-25.52 %	54.6 %
Total Assets in million	8,189	5,782	5,711	6,272	8,421
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	287	-645	-882	-2,004	-1,413
Annual Return On Assets	3.5 %	-11.15 %	-15.44 %	-31.95 %	-16.78 %

ONC's 5 Years Annual ROA >> Back to ONC Management Effectiveness >> Compare ONC ROA to its Competitors

Comment on ONC's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 3.5 % compared to prior year, due to annual net income growth of % to $286.93 million, while value of Beone Medicines Ltd 's overall assets grew just by 41.62 % to $8,188.57 million, compared to $8,188.57 a year before.

More Return On Assets Ratios
ONC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ONC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ONC's Competitors
Subscribers only: Roa for Beone Medicines Ltd 's Suppliers
Subscribers only: Return On Assets for ONC's Customers

You may also want to know
ONC's Roi	ONC's Inventory Turnover Ratio	ONC's Growth Rates	ONC's Dividend Comparisons
	ONC's Profitability Ratios	ONC's Asset Turnover Ratio	ONC's Dividend Growth
ONC's Roe	ONC's Valuation Ratios	ONC's Financial Strength Ratios	ONC's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Protalix Biotherapeutics inc	19.89 %
Electromed Inc	19.73 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Alpha Pro Tech Ltd	12.46 %
Tenet Healthcare Corp	12.39 %
Hca Healthcare Inc	11.73 %
Carlisle Companies Incorporated	11.72 %
Regeneron Pharmaceuticals Inc	11.50 %

Date modified: 2026-11-10T10:37:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.